The event, hosted by Swedish EPP MEP Christofer Fjellner, highlighted the increasingly influential role played by patients in managing their own care and recovery.
So far, more than 350 million patients have benefitted from medicines manufactured through biotechnology and gene technology to treat or prevent heart attacks, strokes, multiple sclerosis, breast cancer, cystic fibrosis, leukemia, hepatitis, diabetes and other diseases. In addition, an estimated 50% of all new medicines will originate from biotechnologies.
Christofer Fjellner commented:
"Today's session has helped raise awareness of the urgent need to update and modernize current legislation on information about medicines. It's evident that we need better access to information about medicines to empower patients all over Europe. To achieve this we need a broad commitment from all European institutions."
To pressrelease by Europabio
Working for a successful life science industry The Life Science Industry has improved the lives of millions of people, has created enormous values and is one of the most beneficial industries to our society. SwedenBIO is one of Europe´s largest industry organisations representing more than 180 exciting member companies in Sweden. SwedenBIO is the industry´s only national organisation with a mission to promote an environment bringing success and growth to the entire Swedish Life Science Industry. Join and follow us: Twitter Linked In Youtube